XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transaction
 9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]  
Related Party Transaction

13. Related Party Transaction

Effective as of May 1, 2018, the Company entered into a subscription license agreement and a services agreement with Revon Systems, Inc. (“Revon”). Under the subscription license agreement, Revon granted the Company an exclusive license to use the Revon software platform and applications for any purpose with respect to the Company's programs in age-related macular degeneration, hemolytic diseases and complement-dependent nephropathies for an annual license fee of $0.2 million for a two year initial term and an option to obtain a perpetual, exclusive license thereafter for $0.4 million. Under the services agreement, Revon provided development services with respect to the Revon software to the Company for $0.3 million during the first year. Prior to the acquisition of Revon by an unrelated third party in July 2019, the Company paid the remainder of the annual license fee due for the second year, exercised the option for the perpetual license and discontinued the services agreement.

Each of Cedric Francois, the Company’s chief executive officer, Pascal Deschatelets, the Company’s chief scientific officer, and Alec Machiels, a member of the board of directors, was an affiliate of Revon. The Board approved the Revon agreements after review by a subcommittee of the disinterested members of the Board and determination by the full Board that the terms of the Revon agreements were fair, reasonable and in the best interests of the Company. The exercise of the option for the perpetual license was approved in accordance with the Company’s related party transaction policy.